Skip to content

Study · Not a test of the peptide alone · 1999

9 results

Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.

Gasperi M, Aimaretti G, Scarcello G, Corneli G, Cosci C, Arvat E, Martino E, Ghigo E

The Journal of clinical endocrinology and metabolism1 Aug 1999Cited by 24 (Europe PMC)

PMID10443652 (opens in a new tab)DOI10.1210/jcem.84.8.5904 (opens in a new tab)PepBankPUB-10443652
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 01HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In normal young adults, the GH peak after the GHRH plus hexarelin test averaged 83.6 microg/L, with third and first percentile limits of 55.5 and 51.2 microg/L.

    In plain wordsIn healthy young adults, a test of GHRH plus hexarelin raised growth hormone to an average peak of 83.6 microg/L.

    Peptide
    Hexarelin
    Outcome
    Not applicableGH peak after GHRH plus hexarelin in normal subjects
    Study

    n = 25

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean GH peak
    83.6 microg/L
    normal subjects
    Third percentile limit
    55.5 microg/L
    normal GH response
    First percentile limit
    51.2 microg/L
    normal GH response

    Source sentences

    Summary
    The mean GH peak after GHRH+HEX in NS was 83.6+/-4.5 microg/L; the third and first percentile limits of the normal GH response were 55.5 and 51.2 microg/L, respectively).
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 02HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, the mean GH peak after GHRH plus hexarelin was similar to that after GHRH plus arginine.

    In plain wordsIn adults with growth hormone deficiency, GHRH plus hexarelin gave a growth hormone peak similar to that of GHRH plus arginine.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH peak after GHRH plus hexarelin versus GHRH plus arginine in GH deficiency
    Study

    n = 19

    Comparator
    GHRH plus arginine
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH peak after GHRH+HEX
    2.6 microg/L
    GH deficiency
    GH peak after GHRH+ARG
    3.6 microg/L
    GH deficiency

    Source sentences

    Summary
    In GHD the mean GH peak after GHRH+HEX (2.6+/-0.7 microg/L) was similar to that after GHRH+ARG (3.6+/-1.0 microg/L), and both were higher (P < 0.001) than that after ITT (0.6+/-0.1 microg/L); the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG.
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 03HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, the mean GH peak after GHRH plus hexarelin was higher than after the insulin-induced hypoglycemia test (P < 0.001).

    In plain wordsIn adults with growth hormone deficiency, GHRH plus hexarelin gave a higher growth hormone peak than the insulin-induced low blood sugar test.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH peak after GHRH plus hexarelin versus insulin-induced hypoglycemia in GH deficiency
    Study

    n = 19

    Comparator
    Insulin-induced hypoglycemia test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH peak after GHRH+HEX
    2.6 microg/L
    GH deficiency
    GH peak after ITT
    0.6 microg/L
    GH deficiency

    Source sentences

    Summary
    In GHD the mean GH peak after GHRH+HEX (2.6+/-0.7 microg/L) was similar to that after GHRH+ARG (3.6+/-1.0 microg/L), and both were higher (P < 0.001) than that after ITT (0.6+/-0.1 microg/L); the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG.
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  4. 04HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, GH responses to GHRH plus hexarelin were positively associated with those to the insulin-induced hypoglycemia test and to GHRH plus arginine.

    In plain wordsIn adults with growth hormone deficiency, responses to GHRH plus hexarelin were linked to responses in the other two tests.

    Peptide
    Hexarelin
    Outcome
    Not applicableAssociation of GH response to GHRH plus hexarelin with ITT and GHRH plus arginine
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG.
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  5. 05HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, all had GH peaks after GHRH plus hexarelin below the third percentile limit of normal (55.5 microg/L).

    In plain wordsIn adults with growth hormone deficiency, every person had a growth hormone peak after GHRH plus hexarelin below the normal limit.

    Peptide
    Hexarelin
    Outcome
    Not applicableGH deficient subjects below the third percentile limit after GHRH plus hexarelin
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Third percentile limit
    55.5 microg/L
    GHRH+HEX

    Source sentences

    Summary
    After GHRH+HEX all GHD had GH peaks below the third percentile limit of normality appropriate for this test (i.e. 55.5 microg/L).
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  6. 06HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, Thirteen of 19 (68.4%) had GH peaks below 3 microg/L after GHRH plus hexarelin.

    In plain wordsIn adults with growth hormone deficiency, thirteen of 19 had a growth hormone peak below 3 microg/L after GHRH plus hexarelin.

    Peptide
    Hexarelin
    Outcome
    Not applicableGH deficient subjects with GH peak below 3 microg/L after GHRH plus hexarelin
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Proportion with GH peak below 3 microg/L
    68.4%
    GH deficiency, GHRH+HEX

    Source sentences

    Summary
    Thirteen of 19 (68.4%) GHD subjects had GH peaks below 3 microg/L after GHRH+HEX
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  7. 07HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, all 19 (100%) had GH peaks after GHRH plus hexarelin below the first percentile limit of normal (51.2 microg/L).

    In plain wordsIn adults with growth hormone deficiency, all 19 had a peak after GHRH plus hexarelin below the first percentile normal limit.

    Peptide
    Hexarelin
    Outcome
    Not applicableGH deficient subjects below the first percentile limit after GHRH plus hexarelin
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Proportion below first percentile limit
    100%
    GH deficiency, GHRH+HEX
    First percentile limit
    51.2 microg/L
    GHRH+HEX

    Source sentences

    Summary
    but all 19 (100%) had GH peaks below the first percentile limit of normality (i.e. 51.2 microg/L).
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  8. 08HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In adults with GH deficiency, individual GH responses to GHRH plus hexarelin were highly concordant with those after GHRH plus arginine.

    In plain wordsIn adults with growth hormone deficiency, individual responses to GHRH plus hexarelin matched those to GHRH plus arginine closely.

    Peptide
    Hexarelin
    Outcome
    Not applicableConcordance of GH responses to GHRH plus hexarelin and GHRH plus arginine
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The GH responses to GHRH+HEX were highly concordant with those after GHRH+ARG.
    1 context sentence
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  9. 09HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In normal young adults, the GH response to the GHRH plus hexarelin test showed good reproducibility within the same person in a second session.

    In plain wordsIn healthy adults, the growth hormone response to GHRH plus hexarelin was similar when the test was repeated in the same person.

    Peptide
    Hexarelin
    Outcome
    Not applicableReproducibility of GH response to GHRH plus hexarelin
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The GH response to GHRH+HEX in NS showed good intraindividual reproducibility.
    2 context sentences
    Summary · context
    in 11 of them verified its reproducibility in a second session
    Summary · context
    Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03223025

Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency

Cinnagenn = 309 Mar 2016 to 4 Feb 2017

Idiopathic Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 31 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.